In February 2025, I sat in a conference room across from a vendor who was about to get my signature on a purchase that would have been a disaster. Not an obvious disaster—a slow one. The kind you don't see until year two.
The proposal was for a robotic surgical system. We were evaluating two platforms: one from Intuitive Surgical, the longtime market leader, and this challenger with a much lower sticker price. The challenger's quote was $1.3 million below Intuitive's. The service contract looked lean. The instrument pricing looked competitive. The rep said the learning curve was manageable. On paper, it was a no-brainer.
Then, right as I reached for the pen, a surgeon I barely knew knocked and poked his head into the room. "Can I borrow you for a second?"
He closed the door behind me and asked a question that made my stomach drop.
"Do you know why they're cheaper?"
I didn't.
How I Got to That Room
Here's the thing about my background: I've spent seven years as director of surgical services for a regional health system, and I've made my share of purchasing mistakes. About $300,000 worth, if I'm honest, documented in a spreadsheet I don't like looking at. I could answer "what is flow cytometry?" in my sleep. I've negotiated contracts for portable oxygen concentrators, imaging towers, and endoscopy carts. I was the person my CFO trusted with capital budgets.
None of that prepared me for a surgical robot.
When I first started the evaluation, I assumed that if the FDA cleared a platform, the systems were roughly equivalent. Maybe one had better marketing, but clinically, a robot is a robot, right?
Wrong. Very, very wrong.
The Rabbit Hole
That surgeon's question sent me down a rabbit hole that consumed most of a week. I called colleagues at three other health systems who'd been through robotic purchases. I asked each of them the same question: what did I not know?
The answer that kept coming up: "Check whether the company will still exist—and still give a damn—in ten years."
That sounds obvious in hindsight. It wasn't in my process.
It took me a week and about a dozen phone calls to realize this wasn't a pricing decision. It was a risk assessment.
So I pulled the financials. Intuitive Surgical's credit rating, per the rating agencies' public reports as of January 2025, is solidly investment grade—S&P: A-, Moody's: A3. I'm not a finance person, but I knew what that meant: this company has the balance sheet to fund R&D, maintain a global service network, and support software upgrades long after our depreciation schedule runs out.
Then I looked at Intuitive Surgical's competition. Some of the newcomers are backed by massive parent companies with deep pockets—no concern there. Others were smaller, with debt loads that made me uneasy. One had launched commercially with a funding round that suggested maybe two years of runway. I don't want to be the hospital that buys a robot from a promising startup that runs out of gas in year three.
Installed Base Is Not a Vanity Metric
Here's something vendors don't tell you: market share matters for reasons that have nothing to do with being cool.
Intuitive's competition has grown more credible, don't get me wrong. But the installed base gap is still enormous. As of late 2024, Intuitive had roughly 9,000+ da Vinci systems installed globally and more than 15 million cumulative procedures, according to the company's public disclosures. When I first saw those numbers, I wrote them off as marketing. I was wrong.
A big installed base means trained surgeons. It means service engineers within a reasonable drive. It means a library of clinical data that tells you what actually happens when things go wrong. It means our team could train at a high-volume center instead of figuring things out alone. That infrastructure has a direct effect on surgical outcomes and OR uptime—the two things that keep me up at night.
Granted, competitors are building their own ecosystems. But "building" is the operative word. I had to make a recommendation in 2025, not 2030.
The Catheter Ablation Conversation That Crushed My Confidence
This is the part that still makes me cringe.
I walked into the evaluation assuming one robotic platform could cover everything we do—soft tissue surgery, thoracic cases, cardiac procedures, all of it. It can't.
Take catheter ablation, for example. I knew the term. I knew the hospital was growing its electrophysiology program. And I assumed that if we bought a surgical robot, it would be a step up for the EP lab too.
A friend of mine in the EP lab corrected me in about ten seconds. "You don't use a general-purpose surgical robot for catheter ablation," she said. "Different catheters. Mapping system. Different everything."
She was right. Catheter ablation is a completely different technical universe from surgical robotics. If I'd presented that assumption to the cardiac team, I would have lost every ounce of credibility I had. That conversation rewired how I looked at the entire decision: not "which robot is the best," but "which system fits the procedures we actually do."
When the Price Advantage Disappeared
And then I built the five-year model.
The $1.3 million price gap that almost won my signature? It melted away. The cheaper system had higher per-procedure instrument costs—the consumables ran about 18% more expensive than the equivalent on the Intuitive platform. The training program was newer and less structured, which meant a longer ramp and fewer cases in year one. The service contract, I discovered, was a bare-bones package that didn't include 24/7 response or replacement robotic arms—the two line items that actually matter when a robot goes down.
By month 21 of my model, the price advantage was completely gone. By year five, the "cheaper" robot would have cost us about 11% more than Intuitive.
Eleven percent. That's the number that scared the hell out of me.
The Checklist I Still Use
I went back to the board with a one-page document instead of a vendor deck. It's a checklist I've used on three major capital purchases since, and honestly, it's the most valuable thing I've produced as a director.
- Vendor financial stability. Credit rating, R&D spending, cash reserves. If a vendor won't share these, that's an answer in itself.
- Five-year total cost. Acquisition price, per-procedure instruments, service tiers, training hours, utilization projections—in that order.
- Installed base and clinical evidence. "FDA-cleared" is the minimum, not the standard. How many systems are running? How many procedures? How many peer-reviewed studies?
- Service and training ecosystem. Response time for parts, availability of service engineers, simulation and training infrastructure for incoming surgeons.
- Procedure fit. What is this system actually designed to do? Is that what our surgeons actually do? (The catheter ablation lesson, in checklist form.)
Since I started using it, the checklist has caught one deal that would have cost us an estimated $400,000 in overpriced service and consumables. That's not a small number for a regional health system.
The Actual Decision
We ended up installing a da Vinci system from Intuitive Surgical. I want to be clear: this wasn't brand loyalty. It was math, plus a risk assessment. The five-year model came in better. The installed base meant our surgeons could train faster. The credit rating meant the company would still be around, with the same service standards, when the next generation of the platform comes out.
The negotiation also surprised me. When a vendor knows you've done your homework, the first quote isn't the last quote. Intuitive's team offered a service agreement that wasn't in the original proposal, which shaved a meaningful chunk off our year-two and year-three costs.
Did we get everything right? No. We underestimated how long surgeon credentialing would take—that pushed our first robotic cases back by about a month. But that's a scheduling problem. We didn't sign a seven-year deal that would have stranded us with a platform that can't support the procedures we need.
What I'd Tell Anyone Starting This Process
If you're evaluating a surgical robot—or honestly any major capital purchase—here's the message I want you to take from this:
The cheapest quote is not a discount. It's a hypothesis. And you're the person responsible for testing it.
I used to think due diligence was busywork. A checkbox before the real decision. Now I call it the cheapest insurance in the capital budget. Three days of checking credit ratings, installed base numbers, and instrument cost models saved us from a seven-year headache that would have been a lot more expensive than the $1.3 million we were initially tempted to save.
Because in the end, the most expensive purchase isn't the one with the highest price tag. It's the one you have to make twice.